Cargando…
CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)
BACKGROUND: Cisplatin (DDP) is the first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC), and long-term DDP stimulation increased resistance of NSCLC cells to this drug by enriching cancer stem cells (CSCs), which contributed to recurrence and worse prognosis of NSCLC, but the mole...
Autores principales: | Zhao, Yongsheng, Zheng, Renyan, Chen, Jian, Ning, Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339514/ https://www.ncbi.nlm.nih.gov/pubmed/32655321 http://dx.doi.org/10.1186/s12935-020-01390-w |
Ejemplares similares
-
CircRNA DONSON contributes to cisplatin resistance in gastric cancer cells by regulating miR-802/BMI1 axis
por: Liu, Yong, et al.
Publicado: (2020) -
Circular RNA circUBAP2 regulates proliferation and invasion of osteosarcoma cells through miR-641/YAP1 axis
por: Wu, Haojie, et al.
Publicado: (2020) -
Effect of the circCDR1as/miR-641/XIAP regulatory axis on the proliferation and invasion of the prostate cancer PC-3 cell line
por: Niu, Yulin, et al.
Publicado: (2021) -
circRNA_103615 contributes to tumor progression and cisplatin resistance in NSCLC by regulating ABCB1
por: Liang, Hongguang, et al.
Publicado: (2021) -
Construction of a circRNA-miRNA-mRNA network based on competitive endogenous RNA reveals the function of circRNAs in osteosarcoma
por: Qiu, Yu, et al.
Publicado: (2020)